Seminars in Oncology
Volume 32, Issue 3 , Pages 329-335, June 2005

Redefining Bronchioloalveolar Carcinoma

  • Janessa J. Laskin

      Affiliations

    • Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
    • Corresponding Author InformationAddress reprint requests to Janessa Laskin, MD, Division of Medical Oncology, BC Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6 Canada
  • ,
  • Alan B. Sandler

      Affiliations

    • Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN
  • ,
  • David H. Johnson

      Affiliations

    • Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

Bronchioloalveolar carcinoma (BAC) is a subtype of non-small cell lung cancer (NSCLC) with distinct clinical and pathologic features. Although BAC appears to be on a pathologic continuum with adenocarcinoma, the most recent World Health Organization (WHO) classification system has set stringent criteria for the diagnosis. Though malignant, these cancers tend to be peripheral and grow in a lepedic fashion along the alveolar septae without parenchymal invasion. This clear distinction based on histopathology allows for a more definite separation of the natural history and behavior of BAC in clinical studies. Recent clinical trials of molecular targeted anticancer therapies have led to a deeper understanding of the unique features of this cancer and suggest that BAC may require a different therapeutic paradigm from other NSCLCs.

 

PII: S0093-7754(05)00083-7

doi:10.1053/j.seminoncol.2005.02.013

Seminars in Oncology
Volume 32, Issue 3 , Pages 329-335, June 2005